|
Indian Pharma Innovation:
Efpia Medicine
|
|
|
|
Efpia Medicine’s has built a portfolio of over 1,600+ formulations across 15 dosage forms. By focusing on high-speed distribution and specialized divisions like Metanoia (Cardiac/Diabetic) and Cider (Neuro/Nephro), they’ve moved beyond being a traditional supplier to becoming a critical infrastructure partner for Tier 2 and Tier 3 healthcare providers.
|
|
With 24-hour dispatch systems and partnerships with India’s manufacturing giants like Akums and Windlas, Efpia is demonstrating how mature scale can drive affordability. As the Union Budget 2026 shifts the spotlight toward “Biopharma SHAKTI,” companies like Efpia are already on the ground, turning policy signals into real-world patient outcomes.
|
|
Interested in exploring their Innovations? Yes!
|
|
|
|
|
|
Welcome to all the supporters of Agenda+Health, here’s is what to expect:
|
Acquistions Spree in Indian Hospitals Landscape Our Podcast with Dr Abhishek Sen (Co-Founder: ButterFly Learnings) Top 5 Startups Transforming Nephrology & Dialysis New Frontiers: Rising MedTech Pioneers Corporate Updates: Indian Healthcare
|
|
Read time: 5 minutes
|
|
|
1/ Acquistions Spree in Indian Hospitals Landscape
|
|
Novo Holdings bought 49% in Paediatric-heavy Surya Hospitals India at ₹1200Cr valuation (₹2.4Cr/Bed).
|
|
Is the premium for Paeds category or West🇮🇳 opportunity capture post-Sahyadri Hospitals‘s unthinkable ₹4.6Cr/Bed purchase by Manipal Hospitals (MHEPL)?
|
|
|
|
You can read deeper perspective and analysis of the acquisitions in Indian Healthcare Landscape and possible predictions on the LinkedIn post.
|
|
|
2/ Our Podcast with Dr Abhishek Sen (Co-Founder: ButterFly Learnings)
|
|
Our Latest Podcast: Dr.Abhishek Sen, cofounder of Butterfly Learnings raised $5.3m to solve the problem of Autism affecting 13m kids today in India ( along with his wife Dr.Sonam Kothari).
|
|
He has not just –
|
|
– expanded Butterfly Learnings to 75 clinics that provide personalised ABA therapy but also
|
|
– launched a CDSCO approved eye-tracking technology (Get SET Early founded by Dr. Karen Pierce) to diagnose Autism as early as 12 months of a child.
|
|
There is a learning for every doctor in this podcast especially the young and fresh doctors who, today more than ever, feel confused post their MBBS as to the future direction.
|
|
|
3/ Top 5 Startups Transforming Nephrology & Dialysis
|
|
With the government’s renewed focus on NCDs (Non-Communicable Diseases), we look at the innovators managing the chronic kidney disease (CKD) crisis:
|
|
The Renal Project is building a network of micro-dialysis centers to bring life-saving treatment closer to Tier 2 and Tier 3 patients.
|
|
Monitra Health’s ‘UpBeat’ platform provides clinical-grade heart and vitals monitoring, essential for managing high-risk cardiac-renal patients.
|
|
Althion Tech Innovations is solving the “water hurdle” in dialysis with their Portable RO Systems specifically for Home and ICU dialysis.
|
|
Renalyx Health Systems have developed RxT21, India’s first indigenously designed, AI-powered smart hemodialysis machine.
|
|
Twin Health’s “Digital Twin” technology to reverse chronic metabolic diseases that lead to kidney failure.
|
|
|
4/ New Frontiers: Rising MedTech Pioneers
|
|
Remidio
|
|
Remidio’s flagship Fundus On Phone (FOP-NM) is a portable, smartphone-based retinal imaging device that captures high-quality images without the need for pupil dilation.
|
|
Combined with their Medios AI, which detects referable diabetic retinopathy in under 10 seconds without an internet connection, Remidio has decentralized screenings.
|
|
|
|
|
Sascan Meditech
|
|
Sascan Meditech, based in Thiruvananthapuram, has successfully commercialized OralScan, ISO 13485 certified, multispectral imaging device for the non-invasive screening of oral cancer.
|
|
OralScan uses biophotonics to detect potentially malignant lesions and provides real-time guidance for biopsies, significantly reducing the “wait and watch” period for high-risk patients.
|
|
|
|
|
|
5/ Corporate Updates: Indian Healthcare
|
Union Finance Minister allocated ₹1,06,530 Crore for 2026-27, a 10% hike focusing on regional medical hubs. (Source) The government has proposed full exemption of basic customs duty on 17 critical drugs to lower the cost of cancer treatment in India. (Source) Launch of a new scheme to support states in setting up five regional “Medical Value Tourism” hubs in partnership with the private sector. (Source) Shares of Max Healthcare, Apollo Hospitals, and Medanta jumped up to 5% following budget announcements on private-sector infrastructure participation. (Source) A ₹10,000 Cr push for biologics and R&D targeting NCDs like Diabetes and Autoimmune disorders was unveiled to make India a global bio-manufacturing hub. (Source)
|
